ew report result beat consensu estim top bottom-
line tavr transcathet aortic valv replac growth acceler underli
meaning step level underli driven fda
low-risk indic august coupl data present march
consequ ew rais total sale tavr sale guidanc year well
compani adj ep outlook look ahead expect ew finish year
commentari may surpris believ larg reflect
manag conservat remain posit bias ew share rais
pt assum ep estim reiter
driven tavr close ew report result total
sale underli y/i street model top-
line beat driven tavr growth underli led busi
grew around level procedur standpoint sale
ew busi larg in-lin street estim forecast adjust
gross margin y/i driven primarili fx hedg benefit
favor product mix off-set manufactur varianc expens
relat eu devic regul adj oper margin came ahead
forecast driven higher sale model coupl lower op ex
spend bottom line adj ep handili consensu
estim driven revenu beat lower op ex spend favor tax rate
guidanc rais ew new full-year guidanc call report sale
top-end guidanc rang compani also updat tavr outlook
report sale expect top-end rang
underli tavr growth nearli vs high-end prior bottom-
line ew guid adj ep previous
compani report sale adj ep guidanc
continu next page
competit price pressur product delay advers clinic data litig
ew develop manufactur sell product treat structur heart diseas
provid critic care monitor market leader tavr valv
ep
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
tavr global tavr sale easili eclips street expect ew tavr
growth strong across geographi led procedur growth
compani estim ou tavr market grew underli ew post
compar growth regard sapien ultra manag said expect valv account
compani european tavr sale
tmtt perform ew tmtt busi perhap one disappoint area
call least view ew post tmtt sale mostli compris pascal
modestli expect manag note compani continu
launch pascal disciplin approach also acknowledg premium price strategi
moder new site activ compani expect total tmtt sale
previou guidanc full-year ew remain optimist
commerci prospect tmtt portfolio expect sale doubl next year behind
addit new site exist new geographi
surgic structur heart critic busi less line street
expect surgic structur heart ssh sale modestli consensu
critic cc sale slightli manag
re-affirmed report sale underli growth outlook ssh cc
quick pipelin recap pipelin standpoint major surpris issu
call although early-tavr expect complet enrol vs previous
understand mitral tricuspid clinic program track line previou
expect ew note begun enrol patient clasp iif pivot trial
serv basi pascal fmr function mitral regurgit approv fda
mitral replac front ew continu expect begin pivot trial sapien
stock wed expect anoth strong print finish year would note
compani tavr guidanc impli similar level tavr growth vs
investor may question initi low double-digit procedur growth outlook tavr
believ compani forecast larg reflect manag conservatismwhich view
prudent stage year although dont expect meaning ep leverag next year
still see double-digit adj ep growth achiev remain posit bias share
ew rais pt base ep vs previous
increas multipl reflect posit outlook reiter overweight rate
page
pjc estim compani report
page
million
sale
revenu report
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
